<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044719</url>
  </required_header>
  <id_info>
    <org_study_id>RBHADS001</org_study_id>
    <nct_id>NCT01044719</nct_id>
  </id_info>
  <brief_title>Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis</brief_title>
  <official_title>What Duration of Intravenous Antibiotic Therapy Should be Used in the Treatment of Infective Exacerbations of Cystic Fibrosis Chronically Colonised With Pseudomonas Aeruginosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic Fibrosis patients attending with infective exacerbations will be enrolled into the
      study. The trial is a double blinded, randomised trial with patients randomised to 10,14 or
      21 days of antibiotic therapy, comprising of tobramycin and either ceftazidime or meropenem.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure at completion of antibiotic course</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to next exacerbation</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Spirometry</measure>
    <time_frame>up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory markers</measure>
    <time_frame>up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sputum bacteriology</measure>
    <time_frame>up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects of study antibiotics</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life scores</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in nutritional status</measure>
    <time_frame>up to 21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>10 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>14 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>21 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftazidime</intervention_name>
    <description>Ceftazidime 2g TDS IV</description>
    <arm_group_label>10 days</arm_group_label>
    <arm_group_label>14 days</arm_group_label>
    <arm_group_label>21 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin</intervention_name>
    <description>Tobramycin 7mg/kg/day OD IV</description>
    <arm_group_label>10 days</arm_group_label>
    <arm_group_label>14 days</arm_group_label>
    <arm_group_label>21 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Meropenem 2g TDS IV</description>
    <arm_group_label>10 days</arm_group_label>
    <arm_group_label>14 days</arm_group_label>
    <arm_group_label>21 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  16 years or older

          -  Diagnosis of Cystic Fibrosis

          -  Presenting with Infective exacerbation

        Exclusion Criteria:

          -  Unable to give consent

          -  Allergy to study medications

          -  Intolerance of aminoglycoside antibiotics

          -  Pseudomonas resistant to study antibiotics

          -  On the active transplant list or FEV1&lt;20% predicted

          -  Pregnancy/breast-feeding

          -  Co-existent ABPA requiring a change in treatment

          -  Co-existent mycobacterial infection

          -  A previous participant in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Hodson, MD FRCP DA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Jones, MB BChir MRCP</last_name>
    <phone>02073518940</phone>
    <email>andrew.jones1@imperial.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cystic Fibrosis, Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>Sw3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2009</study_first_submitted>
  <study_first_submitted_qc>January 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2010</study_first_posted>
  <last_update_submitted>April 12, 2010</last_update_submitted>
  <last_update_submitted_qc>April 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof Margaret Hodson</name_title>
    <organization>Imperial College London</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

